Zuloff-Shani Adi has officially reported his ownership of shares in Evogene Ltd., a key player in the agricultural chemicals sector. This disclosure, filed on October 22, 2026, is significant as it indicates Adi's personal investment in a company that is actively involved in developing innovative solutions for agriculture.
Evogene Ltd., identified by its CIK number 0001574565, operates under the SIC classification for agriculture chemicals. The company is based in Rehovot, Israel, and focuses on leveraging biotechnology to enhance crop productivity and sustainability.
According to the recent SEC filing, Adi is recognized as a director of Evogene Ltd. The filing states, "no securities owned" were reported, but it confirms his role within the company. The filing was made under the SEC Act of 1934, and the period of report is noted as October 6, 2026.
This ownership change may have implications for various stakeholders, including investors, employees, and competitors within the agriculture chemicals industry. As Evogene continues to innovate, Adi's involvement could signal confidence in the company's direction and future projects.
Details were not available in the SEC filing regarding what actions may follow this disclosure.
Details of Ownership and Company Structure
The SEC filing indicates that Zuloff-Shani Adi is a director of Evogene Ltd., which is a critical role in the company's governance and strategic direction. Despite the report stating that no securities are owned by Adi, his directorship suggests a significant level of influence over company decisions and policies.
Evogene Ltd. operates under the Central Index Key (CIK) number 0001574565 and is classified under the Standard Industrial Classification (SIC) code for agriculture chemicals [2870]. The company is incorporated in Israel, with its business address located at 13 Gad Feinstein Street, Park Rehovot, Rehovot, L3, 7638517.
Company Financials and Market Position
While the filing does not provide specific financial data or recent performance metrics for Evogene Ltd., it does highlight the company's focus on biotechnology applications aimed at enhancing agricultural productivity and sustainability. This positioning in the market is critical as the demand for innovative agricultural solutions continues to grow globally.
"The filing was accepted on October 22, 2026, and the reporting period is noted as October 6, 2026, reflecting the timely nature of the disclosure in relation to corporate governance practices."
Furthermore, the filing lacks information on any future plans or initiatives that Adi may be involved in as a director, which could provide insights into Evogene's strategic direction moving forward.